US 11,866,418 B2
Substituted benzofuran, benzopyrrole, benzothiophene, and structurally related complement inhibitors
Pravin L. Kotian, Hoover, AL (US); Yarlagadda S. Babu, Birmingham, AL (US); Weihe Zhang, Vestavia Hills, AL (US); Peng-Cheng Lu, Vestavia Hills, AL (US); Minwan Wu, Vestavia Hills, AL (US); Wei Lv, Hoover, AL (US); Trung Xuan Nguyen, Hoover, AL (US); Zhao Dang, Vestavia Hills, AL (US); Venkat R. Chintareddy, Vestavia Hills, AL (US); V. Satish Kumar, Birmingham, AL (US); and Krishnan Raman, Birmingham, AL (US)
Assigned to BioCryst Pharmaceuticals, Inc., Durham, NC (US)
Filed by BioCryst Pharmaceuticals, Inc., Durham, NC (US)
Filed on Apr. 27, 2022, as Appl. No. 17/730,438.
Application 17/730,438 is a division of application No. 17/202,965, filed on Mar. 16, 2021, granted, now 11,370,774.
Application 17/202,965 is a continuation of application No. 16/511,642, filed on Jul. 15, 2019, granted, now 11,021,458.
Application 16/511,642 is a continuation of application No. PCT/US2019/026054, filed on Apr. 5, 2019.
Claims priority of provisional application 62/654,108, filed on Apr. 6, 2018.
Prior Publication US 2023/0099716 A1, Mar. 30, 2023
This patent is subject to a terminal disclaimer.
Int. Cl. C07D 401/10 (2006.01); C07D 209/12 (2006.01); C07D 261/20 (2006.01); C07D 307/80 (2006.01); C07D 333/64 (2006.01); C07D 401/12 (2006.01); C07D 405/10 (2006.01)
CPC C07D 401/10 (2013.01) [C07D 209/12 (2013.01); C07D 261/20 (2013.01); C07D 307/80 (2013.01); C07D 333/64 (2013.01); C07D 401/12 (2013.01); C07D 405/10 (2013.01)] 17 Claims
 
1. A method of treating a disease or condition characterized by aberrant complement system activity, comprising administering to a subject in need thereof a therapeutically effective amount of a compound, or a pharmaceutically acceptable salt thereof, selected from the group consisting of:

OG Complex Work Unit Chemistry

OG Complex Work Unit Chemistry
wherein the disease or condition characterized by aberrant complement system activity is selected from the group consisting of age-related macular degeneration (AMD), atypical hemolytic uremic syndrome, membranoproliferative glomerulonephritis, dense deposit disease, paroxysmal nocturnal hemoglobinuria (PNH), organ transplant rejection, myasthenia gravis, neuromyelitis optica, cold agglutinin disease, catastrophic antiphospholipid syndrome, antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV), IgA nephropathy, warm autoimmune hemolytic anemia, and focal segmental glomerulosclerosis.